Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 7/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346526 | 0.84 | MAP3K5 (0.72) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL16758710 | 0.81 | MAP3K5 (0.69) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL10410696 | 0.80 | MAP3K5 (0.67) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL887133 | 0.79 | MAP3K5 (0.65) | MAP3K5PDPK1GDAPIN1POLB | |
| SCHEMBL2891519 | 0.78 | MAP3K5 (0.64) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL6318896 | 0.77 | MAP3K5 (0.61) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL4453628 | 0.76 | MAP3K5 (0.58) | MAP3K5PDPK1GDANUDT1PIN1 | |
| 2,6-Diaminopurine SCHEMBL29143272 | 0.76 | PDPK1 (0.92) | MAP3K5PDPK1GDAPIN1CDK2 | |
| SCHEMBL432161 | 0.76 | PAK1 (0.66) | MAP3K5PDPK1GDANUDT1PIN1 | |
| SCHEMBL320850 | 0.76 | PDPK1 (0.66) | MAP3K5PDPK1GDAPIN1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-09-01 | — | — | US | claimed |
| WO-2021007283-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-01-14 | — | — | WO | claimed |
| EP-2177606-A2 | N-deoxyribosyltransferases from lactobacillus, corresponding nucleotide sequences and their applications | INSTITUT PASTEUR (FR) | 2010-04-21 | — | — | EP | claimed |
| EP-1427819-B1 | LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES | PASTEUR INSTITUT (FR) | 2009-12-23 | — | — | EP | claimed |
| US-20080280329-A1 | Enzymatic synthesis of deoxyribonucleosides | TISCHER WILHELM | 2008-11-13 | — | — | US | claimed |
| US-20080250513-A1 | LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES | INSTITUT PASTEUR (FR) | 2008-10-09 | — | — | US | claimed |
| CN-101217999-A | Personal care compositions and methods for the beautification of mammalian skin and hair | PROCTER & GAMBLE (US) | 2008-07-09 | — | — | CN | claimed |
| EP-1901817-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THE BEAUTIFICATION OF MAMMALIAN SKIN AND HAIR | The Procter and Gamble Company (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2007007255-A2 | PERSONAL CARE COMPOSITIONS AND METHODS FOR THE BEAUTIFICATION OF MAMMALIAN SKIN AND HAIR | THE PROCTER & GAMBLE COMPANY (US) | 2007-01-18 | — | — | WO | claimed |
| EP-0626387-A1 | Nucleosides and oligonucleotides with 2'-ether groups | CIBA-GEIGY AG (CH) | 1994-11-30 | — | — | EP | claimed |
| EP-0612994-A2 | Matrix for matrix-assisted laser desorption mass spectroscopy | CIBA-GEIGY AG (CH) | 1994-08-31 | — | — | EP | claimed |
| US-5332814-A | Process for the preparation of carbacyclic nucleosides, and intermediates | CIBA-GEIGY CORPORATION (US) | 1994-07-26 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273689-A1 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | NSUN3, NSUN2, RNMT | MAP3K5 3594/4885PDPK1 2989/4885GDA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.